Valuation : UCB

Market Cap 40.15B 46.66B 37.78B 34.51B 64.56B 4,406B 64.74B 446B 173B 2,260B 175B 171B 7,282B P/E 2026 *
21x
P/E 2027 * 17.4x
Enterprise Value 40.46B 47.02B 38.07B 34.77B 65.05B 4,439B 65.23B 450B 175B 2,278B 177B 173B 7,338B EV / Sales 2026 *
4.65x
EV / Sales 2027 * 3.96x
Free-Float
61.59%
Yield 2026 *
0.69%
Yield 2027 * 0.71%
1 day+2.71%
1 week+1.78%
Current month+1.78%
1 month-1.21%
3 months-17.91%
6 months-18.96%
Current year-13.03%
1 week 241.56
Extreme 241.56
268.09
1 month 241.56
Extreme 241.56
269.34
Current year 241.56
Extreme 241.56
345.39
1 year 225.65
Extreme 225.65
345.39
3 years 69.7
Extreme 69.7
345.39
5 years 68.3
Extreme 68.301062
345.39
10 years 58.42
Extreme 58.42
345.39
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
+2.71%+1.78% - - 46.66B
-1.87%+4.22%+45.93%-0.47% 82.65B
-0.57%+1.27%-17.24%-34.99% 60.24B
-2.23%+5.48%+499.46%+29.31% 58.11B
-2.03%-2.62%-7.46%+27.87% 49.68B
-4.58%-2.73%+2.93%+157.71% 46.66B
-1.64%+1.07%+57.80%-17.34% 32.63B
-0.98%+1.91%+48.35%+95.93% 25.69B
-0.19%-4.74%+2.30%+196.81% 22.73B
-1.13%-2.45%+65.99%+110.75% 16.51B
Average -1.12%-0.24%+77.56%+62.84% 43.88B
Weighted average by Cap. -1.21%+0.74%+90.70%+41.79%

Financials

2026 *2027 *
Net sales 8.69B 10.1B 8.18B 7.47B 13.98B 954B 14.02B 96.67B 37.51B 489B 37.94B 37.12B 1,577B 9.68B 11.25B 9.1B 8.32B 15.56B 1,062B 15.6B 108B 41.75B 545B 42.23B 41.31B 1,755B
Net income 1.93B 2.24B 1.82B 1.66B 3.11B 212B 3.11B 21.47B 8.33B 109B 8.43B 8.24B 350B 2.32B 2.7B 2.19B 2B 3.74B 255B 3.75B 25.85B 10.03B 131B 10.14B 9.92B 422B
Net Debt 306M 355M 287M 263M 491M 33.52B 493M 3.4B 1.32B 17.2B 1.33B 1.3B 55.41B -1.81B -2.1B -1.7B -1.55B -2.91B -198B -2.91B -20.1B -7.8B -102B -7.89B -7.72B -328B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
04/09/26 $255.34 +2.71% 72
03/09/26 $248.60 -5.87% 69
02/09/26 $264.09 +4.73% 389
01/09/26 $252.16 +0.51% 84
28/08/26 $250.88 -6.24% 16
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
210.60EUR
Average target price
285.00EUR
Spread / Average Target
+35.33%

Quarterly revenue - Rate of surprise